Lidds AB

Lidds AB is an innovative pharmaceutical company specializing in the development of unique drug delivery technologies. At the heart of their work is the proprietary NanoZolid technology, which enhances the efficacy and reduces the side effects of pharmaceutical treatments through controlled and sustained release of medication. Lidds AB's advancements primarily benefit the oncology sector, where prolonged release can significantly improve patient outcomes and quality of life. This technology can be applied across various medical conditions, broadening its potential impact across diverse therapeutic areas. The company's focus on cutting-edge drug delivery systems positions it as a significant player within the biotechnology and pharmaceutical industries, addressing unmet medical needs and contributing to the advancement of personalized medicine. Headquartered in Sweden, Lidds AB is at the forefront of merging pharmaceutical innovation with state-of-the-art delivery systems to revolutionize patient treatment paradigms globally.